Metabotropic glutamate receptor 5 antagonism with fenobam: Examination of analgesic tolerance and side effect profile in mice

Anesthesiology

Volumn 115, Issue 6, 2011, Pages 1239-1250

  Montana, Michael C ^a   Conrardy, Beth A ^a   Cavallone, Laura F ^a   Kolber, Benedict J ^a   Rao, Lesley K ^a   Greco, Suellen C ^a   Gereau, Robert W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENOBAM; METABOTROPIC RECEPTOR 5;

ANALGESIC ACTIVITY; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; COORDINATION; DRUG TOLERANCE; FOOD INTAKE; HEMATOLOGY; HISTOPATHOLOGY; LIVER FUNCTION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; TESTIS; WEIGHT GAIN;

ANALGESICS; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; EATING; IMIDAZOLES; MALE; MICE; MOTOR ACTIVITY; PAIN; PAIN MEASUREMENT; RECEPTORS, METABOTROPIC GLUTAMATE; WEIGHT GAIN;

EID: 81855221702     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e318238c051     Document Type: Article

References (30)

1. Niswender CM, Conn PJ: Metabotropic glutamate receptors: Physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 2010; 50:295-322
2. Conn PJ: Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann N Y Acad Sci 2003; 1003:12-21
3. Varney MA, Gereau RW: Metabotropic glutamate receptor involvement in models of acute and persistent pain: Prospects for the development of novel analgesics. Curr Drug Target CNS Neurol Disord 2002; 1:283-96
4. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, Hutchison J, Snape M, Tranfaglia M, Nguyen DV, Hagerman R: A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 2009; 46: 266-71
5. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat Med 2007; 13:1102-7
6. Bhave G, Karim F, Carlton SM, Gereau RW 4th: Peripheral group I metabotropic glutamate receptors modulate nociception in mice. Nat Neurosci 2001; 4:417-23
7. Karim F, Wang CC, Gereau RW 4th: Metabotropic glutamate receptor subtypes 1 and 5 are activators of extracellular signal-regulated kinase signaling required for inflammatory pain in mice. J Neurosci 2001; 21:3771-9
8. Kolber BJ, Montana MC, Carrasquillo Y, Xu J, Heinemann SF, Muglia LJ, Gereau RWt: Activation of metabotropic glutamate receptor 5 in the amygdala modulates pain-like behavior. J Neurosci 2010;30: 8203-13
9. Zhu CZ, Wilson SG, Mikusa JP, Wismer CT, Gauvin DM, Lynch JJ, 3rd, Wade CL, Decker MW, Honore P: Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur J Pharmacol 2004; 506:107-18
10. Montana MC, Cavallone LF, Stubbert KK, Stefanescu AD, Kharasch ED, Gereau RW 4th: The mGlu5 antagonist fenobam is analgesic and has improved in vivo selectivity as compared to the prototypical antagonist MPEP. J Pharmacol Exp Ther 2009; 330:834-43
11. Jacob W, Gravius A, Pietraszek M, Nagel J, Belozertseva I, Shekunova E, Malyshkin A, Greco S, Barberi C, Danysz W: The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning. Neuropharmacology 2009; 57:97-108
12. Marin JC, Goadsby PJ: Glutamatergic fine tuning with ADX-10059: A novel therapeutic approach for migraine? Expert Opin Investig Drugs 2010; 19:555-61
13. Porter RH, Jaeschke G, Spooren W, Ballard TM, Bttelmann B, Kolczewski S, Peters JU, Prinssen E, Wichmann J, Vieira E, Mhlemann A, Gatti S, Mutel V, Malherbe P: Fenobam: A clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 2005; 315:711-21
14. Pecknold JC, McClure DJ, Appeltauer L: Fenobam in anxious outpatients. Curr Ther Res 1980; 27:119-23
15. Pecknold JC, McClure DJ, Appeltauer L, Wrzesinski L, Allan T: Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J Clin Psychopharmacol 1982; 2:129-33
16. Friedmann CTH, Davis LJ, Ciccone PE, Rubin RT: Phase II double blind controlled study of a new anxiolytic, fenobam (McN-3377) versus placebo. Curr Ther Res 1980; 27:144-51
17. Lapierre Y, Oyewumi L: Fenobam: Another anxiolytic? Curr Ther Res 1982; 31:95-101
18. Bradbury MJ, Campbell U, Giracello D, Chapman D, King C, Tehrani L, Cosford ND, Anderson J, Varney MA, Strack AM: Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice. J Pharmacol Exp Ther 2005; 313:395-402
19. Xu J, Zhu Y, Contractor A, Heinemann SF: mGluR5 has a critical role in inhibitory learning. J Neurosci 2009; 29: 3676-84
20. Jia Z, Lu Y, Henderson J, Taverna F, Romano C, Abramow-Newerly W, Wojtowicz JM, Roder J: Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. Learn Mem 1998; 5:331-43
21. Kolber BJ, Boyle MP, Wieczorek L, Kelley CL, Onwuzurike CC, Nettles SA, Vogt SK, Muglia LJ: Transient early-life forebrain corticotropin-releasing hormone elevation causes longlasting anxiogenic and despair-like changes in mice. J Neurosci 2010; 30:2571-81
22. Wozniak DF, Hartman RE, Boyle MP, Vogt SK, Brooks AR, Tenkova T, Young C, Olney JW, Muglia LJ: Apoptotic neurodegeneration induced by ethanol in neonatal mice is associated with profound learning/memory deficits in juveniles followed by progressive functional recovery in adults. Neurobiol Dis 2004; 17:403-14
23. Spooren WP, Gasparini F, Bergmann R, Kuhn R: Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. Eur J Pharmacol 2000; 406:403-10
24. Sevostianova N, Danysz W: Analgesic effects of mGlu1 and mGlu5 receptor antagonists in the rat formalin test. Neuropharmacology 2006; 51:623-30
25. Felson DT, Zhang Y, Hannan MT, Naimark A, Weissman B, Aliabadi P, Levy D: Risk factors for incident radiographic knee osteoarthritis in the elderly: The Framingham Study. Arthritis Rheum 1997; 40:728-33
26. Martin K, Fontaine KR, Nicklas BJ, Dennis KE, Goldberg AP, Hochberg MC: Weight loss and exercise walking reduce pain and improve physical functioning in overweight postmenopausal women with knee osteoarthritis. J Clin Rheumatol 2001; 7:219-23
27. Zerbib F, Bruley des Varannes S, Roman S, Tutuian R, Galmiche JP, Mion F, Tack J, Malfertheiner P, Keywood C: Randomised clinical trial: Effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2011; 33:911-21
28. Storto M, de Grazia U, Knpfel T, Canonico PL, Copani A, Richelmi P, Nicoletti F, Vairetti M: Selective blockade of mGlu5 metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage. Hepatology 2000; 31: 649-55
29. Son WC: Factors contributory to early death of young CD-1 mice in carcinogenicity studies. Toxicol Lett 2003; 145: 88-98
30. Gad SC. Animal Models in Toxicology, 2nd edition. Boca Raton, CRC Press-Taylor & Francis Group, 2007; pp 64-5